Iluvien for DME available in UK

Article

Iluvien, an intravitreal implant, is now available as a treatment for chronic diabetic macular oedema (DME) in the UK.

Iluvien, an intravitreal implant, is now available as a treatment for chronic diabetic macular oedema (DME) in the UK, announced the latest press release from Alimera Sciences.

The biopharmaceutical company has also submitted a simple Patient Access Scheme (PAS) to the UK's National Institute for Health and Care Excellence (NICE). If successful, this means Iluvien will be funded for chronic DME patients in England and Wales by the NHS.

Dr Simon Horgan, FRCS, FRCOphth, consultant ophthalmic surgeon at St George's Hospital and Moorfields Eye Hospital, London, UK, commented, "I am pleased to be able to finally offer this new sustained release treatment to my private pay and privately insured patients, who suffer from vision impairment associated with chronic DME. Iluvien is a welcome option for DME patients, who no longer respond to conventional therapies and who are facing progression to blindness. I am hoping that in the near future many more patients who are likely to benefit from this treatment will be offered Iluvien."

Dan Myers, president and chief executive officer of Alimera Sciences, added, "We continue to work with NICE and are hopeful that our simple Patient Access Scheme will make Iluvien available to a larger group of chronic DME patients in England and Wales, who are considered insufficiently responsive to available therapies."

NICE will discuss the Iluvien PAS submission on 15 May. For more information on Iluvien please click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.